Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamas Erdei

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Molecules (Basel, Switzerland)|May 24, 2017
Methodical Challenges and a Possible Resolution in the Assessment of Receptor Reserve for Adenosine, an Agonist with Short Half-LifeJudit Zsuga, Tamas Erdei, Katalin Szabó, et al.
Molecules (Basel, Switzerland)|June 20, 2019
An Advanced In Silico Modelling of the Interaction between FSCPX, an Irreversible A<sub>1</sub> Adenosine Receptor Antagonist, and NBTI, a Nucleoside Transport Inhibitor, in the Guinea Pig AtriumAdrienn Monika Szabo, Tamas Erdei, Gabor Viczjan, et al.
General Physiology and Biophysics|November 25, 2024
The ex vivo effects of hypoxanthine-tricyclano, a synthetic adenosine analogue, on rat left and right atriaIgnac Ovari, Gabor Viczjan, Miklos Bege, et al.
Frontiers in Pharmacology|June 27, 2025
The flexibility of SABRE, a new quantitative receptor function model, when fitting challenging concentration-effect dataBarbara Olah, Vera Tarjanyi, Barbara Takacs, et al.
International Journal of Molecular Sciences|September 28, 2021
A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A<sub>1</sub> Adenosine Receptor Antagonist So FarGabor Viczjan, Tamas Erdei, Ignac Ovari, et al.
Circulation. Cardiovascular Imaging|April 18, 2018
Machine Learning Analysis of Left Ventricular Function to Characterize Heart Failure With Preserved Ejection FractionSergio Sanchez-Martinez, Nicolas Duchateau, Tamas Erdei, et al.
Frontiers in Pharmacology|November 6, 2025
The interaction of AB-680, a CD73 inhibitor, with NBTI, a nucleoside transporter inhibitor, on the adenosinergic control of atrial contractilityIgnac Ovari, Agnes Boglarka Brezniczky, Attila Laczovics, et al.
Molecules (Basel, Switzerland)|September 12, 2018
FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig AtriumTamas Erdei, Adrienn Monika Szabo, Nora Lampe, et al.
International Journal of Molecular Sciences|December 18, 2019
Accuracy and Precision of the Receptorial Responsiveness Method (RRM) in the Quantification of A<sub>1</sub> Adenosine Receptor AgonistsAdrienn Monika Szabo, Gabor Viczjan, Tamas Erdei, et al.
Frontiers in Pharmacology|January 2, 2023
The effect of a long-term treatment with cannabidiol-rich hemp extract oil on the adenosinergic system of the zucker diabetic fatty (ZDF) rat atriumGabor Viczjan, Anna Szilagyi, Barbara Takacs, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Molecules (Basel, Switzerland)|May 24, 2017
Methodical Challenges and a Possible Resolution in the Assessment of Receptor Reserve for Adenosine, an Agonist with Short Half-LifeJudit Zsuga, Tamas Erdei, Katalin Szabó, et al.
Molecules (Basel, Switzerland)|June 20, 2019
An Advanced In Silico Modelling of the Interaction between FSCPX, an Irreversible A<sub>1</sub> Adenosine Receptor Antagonist, and NBTI, a Nucleoside Transport Inhibitor, in the Guinea Pig AtriumAdrienn Monika Szabo, Tamas Erdei, Gabor Viczjan, et al.
General Physiology and Biophysics|November 25, 2024
The ex vivo effects of hypoxanthine-tricyclano, a synthetic adenosine analogue, on rat left and right atriaIgnac Ovari, Gabor Viczjan, Miklos Bege, et al.
Frontiers in Pharmacology|June 27, 2025
The flexibility of SABRE, a new quantitative receptor function model, when fitting challenging concentration-effect dataBarbara Olah, Vera Tarjanyi, Barbara Takacs, et al.
International Journal of Molecular Sciences|September 28, 2021
A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A<sub>1</sub> Adenosine Receptor Antagonist So FarGabor Viczjan, Tamas Erdei, Ignac Ovari, et al.
Circulation. Cardiovascular Imaging|April 18, 2018
Machine Learning Analysis of Left Ventricular Function to Characterize Heart Failure With Preserved Ejection FractionSergio Sanchez-Martinez, Nicolas Duchateau, Tamas Erdei, et al.
Frontiers in Pharmacology|November 6, 2025
The interaction of AB-680, a CD73 inhibitor, with NBTI, a nucleoside transporter inhibitor, on the adenosinergic control of atrial contractilityIgnac Ovari, Agnes Boglarka Brezniczky, Attila Laczovics, et al.
Molecules (Basel, Switzerland)|September 12, 2018
FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig AtriumTamas Erdei, Adrienn Monika Szabo, Nora Lampe, et al.
International Journal of Molecular Sciences|December 18, 2019
Accuracy and Precision of the Receptorial Responsiveness Method (RRM) in the Quantification of A<sub>1</sub> Adenosine Receptor AgonistsAdrienn Monika Szabo, Gabor Viczjan, Tamas Erdei, et al.
Frontiers in Pharmacology|January 2, 2023
The effect of a long-term treatment with cannabidiol-rich hemp extract oil on the adenosinergic system of the zucker diabetic fatty (ZDF) rat atriumGabor Viczjan, Anna Szilagyi, Barbara Takacs, et al.
Pageof 3